CF PharmTech, Inc. (HKG:2652)
Hong Kong · Delayed Price · Currency is HKD 11.00
+0.37 (3.48%)
Sep 18, 2026, 4:08 PM HKT
CF PharmTech Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 436.8 | 432.52 | 607.75 | 556.42 | 349.13 | 41.99 | |
Revenue Growth | - | -28.83% | 9.22% | 59.38% | 731.54% | 764.11% |
Cost of Revenue | 103.91 | 104.58 | 116.38 | 101.85 | 83.46 | 21.78 |
Gross Profit | 332.88 | 327.94 | 491.37 | 454.57 | 265.67 | 20.2 |
Selling, General & Admin | 210.55 | 218.3 | 364.66 | 319.93 | 243.81 | 138.88 |
Research & Development | 124.42 | 124.55 | 121.85 | 132.79 | 107.23 | 98.46 |
Other Operating Expenses | -0.1 | -0.1 | 0.04 | - | - | 0.77 |
Operating Expenses | 341.21 | 348.08 | 487.83 | 452.4 | 351.45 | 238.1 |
Operating Income | -8.33 | -20.15 | 3.54 | 2.17 | -85.78 | -217.9 |
Interest Expense | -3.28 | -2.54 | -1.78 | -0.17 | -0.16 | -0.14 |
Interest & Investment Income | 6.81 | 2.15 | 0.61 | 3.92 | 4.29 | 20.71 |
Earnings From Equity Investments | -1.35 | -0.17 | -0.07 | -0.1 | - | - |
Currency Exchange Gain (Loss) | - | - | - | -0.2 | 2.5 | -1.76 |
Other Non Operating Income (Expenses) | -8.6 | 4.06 | 8.51 | 16.82 | 8.54 | -0.08 |
EBT Excluding Unusual Items | -14.76 | -16.65 | 10.8 | 22.44 | -70.62 | -199.18 |
Gain (Loss) on Sale of Investments | -7.14 | 3.24 | 8.38 | - | - | 0.44 |
Gain (Loss) on Sale of Assets | - | - | - | - | - | -0.01 |
Asset Writedown | - | - | - | - | - | -0.02 |
Other Unusual Items | - | - | - | - | - | 4.57 |
Pretax Income | -21.89 | -13.41 | 19.18 | 22.44 | -70.62 | -194.2 |
Income Tax Expense | -15.1 | -15.89 | -1.9 | -9.28 | -21.22 | -62.47 |
Net Income | -6.79 | 2.49 | 21.09 | 31.73 | -49.4 | -131.73 |
Net Income to Common | -6.79 | 2.49 | 21.09 | 31.73 | -49.4 | -131.73 |
Net Income Growth | - | -88.22% | -33.53% | - | - | - |
Shares Outstanding (Basic) | 398 | 378 | 371 | 371 | 371 | - |
Shares Outstanding (Diluted) | 398 | 378 | 371 | 371 | 371 | - |
Shares Change | 6.09% | 1.85% | - | - | - | - |
EPS (Basic) | -0.02 | 0.01 | 0.06 | 0.09 | -0.13 | - |
EPS (Diluted) | -0.02 | 0.01 | 0.06 | 0.09 | -0.13 | - |
EPS Growth | - | -88.43% | -33.53% | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | - | -222.96 | -71.2 | 1.65 | -45.72 | -247.95 |
Free Cash Flow Per Share | - | -0.59 | -0.19 | 0.00 | -0.12 | - |
Gross Margin | 76.21% | 75.82% | 80.85% | 81.69% | 76.09% | 48.12% |
Operating Margin | -1.91% | -4.66% | 0.58% | 0.39% | -24.57% | -518.98% |
Profit Margin | -1.55% | 0.57% | 3.47% | 5.70% | -14.15% | -313.74% |
Free Cash Flow Margin | - | -51.55% | -11.72% | 0.30% | -13.10% | -590.55% |
EBITDA | 56.51 | 42.84 | 57.23 | 50.53 | -51.53 | -191.71 |
EBITDA Margin | 12.94% | 9.90% | 9.42% | 9.08% | -14.76% | - |
D&A For EBITDA | 64.83 | 62.99 | 53.69 | 48.37 | 34.25 | 26.19 |
EBIT | -8.33 | -20.15 | 3.54 | 2.17 | -85.78 | -217.9 |
EBIT Margin | -1.91% | -4.66% | 0.58% | 0.39% | -24.57% | - |
Advertising Expenses | - | - | - | 165.59 | 93.59 | - |